DDrare: Database of Drug Development for Rare Diseases

278. 巨大リンパ管奇形（頚部顔面病変）
［臨床試験数：19，薬物数：23（DrugBank：7），標的遺伝子数：5，標的パスウェイ数：62］

Searched query = "Huge lymphatic malformation with cervicofacial lesion", "Huge lymphatic malformation", "Lymphatic malformation"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = Bleomycin; Device: MRI; Indocyanine green; L04AA10; OK432; Picibanil; Propranolol; RAPAMUNE; Rapamune; Rapamycin; Rapamycin dosage; SIROLIMUS; Selenium; Sildenafil; Sildenafil 20 mg tablets; Sirolimus; Sirolimus 0,1% crème; Sirolimus 1mg/mL; Sirolimus Oral Liquid Product 1mg/mL; Topical 0.1% Sirolimus; Topical Vehicle; VT30; Water

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00010452 (ClinicalTrials.gov)	April 2000	2/2/2001	Study of Picibanil (OK432) Sclerotherapy in Children With Macrocystic Lymphatic Malformations	Treatment of Cystic Hygroma (Lymphangiomas) in Children- Picibanil(OK432) Sclerotherapy-Multicenter Trial	Lymphatic Malformations	Drug: picibanil	University of Iowa	NULL	Completed	6 Months	18 Years	Both	150	Phase 2;Phase 3	United States
2	NCT03427619 (ClinicalTrials.gov)	January 1, 1998	10/1/2018	OK432 (Picibanil) in the Treatment of Lymphatic Malformations	OK432 (Picibanil) in the Treatment of Lymphatic Malformations	Lymphatic Malformations	Drug: OK432	Richard JH Smith	NULL	Completed	6 Months	17 Years	All	701	Phase 4	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT00010452
(ClinicalTrials.gov)

April 2000

2/2/2001

Study of Picibanil (OK432) Sclerotherapy in Children With Macrocystic Lymphatic Malformations

Treatment of Cystic Hygroma (Lymphangiomas) in Children- Picibanil(OK432) Sclerotherapy-Multicenter Trial

Lymphatic Malformations

Drug: picibanil

University of Iowa

NULL

Completed

6 Months

18 Years

Both

150

Phase 2;Phase 3

United States

NCT03427619
(ClinicalTrials.gov)

January 1, 1998

10/1/2018

OK432 (Picibanil) in the Treatment of Lymphatic Malformations

Lymphatic Malformations

Drug: OK432

Richard JH Smith

NULL

Completed

6 Months

17 Years

All

701

Phase 4

United States